Find Darolutamide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

0

API

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Odm-201, 1297538-32-9, Bay-1841788, Nubeqa, Bay1841788, Darolutamide [usan]
Molecular Formula
C19H19ClN6O2
Molecular Weight
398.8  g/mol
InChI Key
BLIJXOOIHRSQRB-PXYINDEMSA-N
FDA UNII
X05U0N2RCO

Darolutamide
Darolutamide is a formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.
1 2D Structure

Darolutamide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
2.1.2 InChI
InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1
2.1.3 InChI Key
BLIJXOOIHRSQRB-PXYINDEMSA-N
2.1.4 Canonical SMILES
CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O
2.1.5 Isomeric SMILES
C[C@@H](CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O
2.2 Other Identifiers
2.2.1 UNII
X05U0N2RCO
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Nubeqa

2. Odm-201

3. Orm-16497

4. Orm-16555

2.3.2 Depositor-Supplied Synonyms

1. Odm-201

2. 1297538-32-9

3. Bay-1841788

4. Nubeqa

5. Bay1841788

6. Darolutamide [usan]

7. N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide

8. Bay 1841788

9. X05u0n2rco

10. Odm-201;bay-1841788

11. 1h-pyrazole-3-carboxamide, N-((1s)-2-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)-1-methylethyl)-5-(1-hydroxyethyl)-

12. N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)-propan-2-yl)-3-(1-hydroxyethyl)-1h-pyrazole-5-carboxamide

13. Odm201

14. 1h-pyrazole-3-carboxamide, N-[(1s)-2-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-

15. Nebeqa (tn)

16. Darolutamide [mi]

17. Odm-201(darolutamide)

18. Darolutamide [inn]

19. Darolutamide [jan]

20. Unii-x05u0n2rco

21. Darolutamide (odm-201)

22. Darolutamide [who-dd]

23. Darolutamide (jan/usan/inn)

24. Schembl1814935

25. Chembl4297185

26. Schembl13733117

27. Gtpl10439

28. Ex-a759

29. Bdbm309979

30. Darolutamide [orange Book]

31. Dtxsid101027953

32. Example 56 [us9657003]

33. N-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide

34. Bdbm50556205

35. Mfcd29472270

36. Nsc825331

37. Akos030526387

38. Ccg-268640

39. Cs-5174

40. Db12941

41. Nsc-825331

42. Ncgc00484078-01

43. Ac-32628

44. As-75032

45. Bay-1841788)

46. Hy-16985

47. S7559

48. J3.501.129c

49. D11045

50. Us9657003, 56

51. A888821

52. J-690121

53. Q25091391

54. 1-[(2s)-2-butanyl]-n-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-1h-indole-4-car Boxamide

55. N-((2s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol- 1-yl)propan-2-yl)-5-((1rs)-1-hydroxyethyl)-1h-pyrazole- 3-carboxamide

56. N-((2s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)propan-2-yl)-5-((1rs)-1-hydroxyethyl)-1h-pyrazole-3-carboxamide

57. N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol -1-yl)propan-2-yl)-3-(1-hydroxyethyl)-1h-pyrazole-5-carboxamide

58. N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxy-ethyl)-1h-pyrazole-3-carboxamide

59. N-[(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide

2.4 Create Date
2012-11-30
3 Chemical and Physical Properties
Molecular Weight 398.8 g/mol
Molecular Formula C19H19ClN6O2
XLogP31.8
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass398.1258016 g/mol
Monoisotopic Mass398.1258016 g/mol
Topological Polar Surface Area120 Ų
Heavy Atom Count28
Formal Charge0
Complexity598
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

This drug is indicated for the treatment of patients diagnosed with non-metastatic and castrate-resistant prostate cancer.


FDA Label


Nubeqa is indicated for the treatment of adult men with non metastatic castration resistant prostate cancer (nmCRPC) who are at risk of developing metastatic disease.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Darolutamide, through its downstream effects on cancer cell growth, treats castrate-resistant prostate cancer. It inhibits cancer cell growth and markedly lowers prostate specific antigen (PSA) levels through potent androgen receptor antagonism.


5.2 ATC Code

L02BB


L - Antineoplastic and immunomodulating agents

L02 - Endocrine therapy

L02B - Hormone antagonists and related agents

L02BB - Anti-androgens

L02BB06 - Darolutamide


5.3 Absorption, Distribution and Excretion

Absorption

Darolutamide is absorbed in the gastrointestinal tract. In the fasted state, peak concentrations are reached within 3-5 hours, and within 3-8 hours in the fed state. Median Tmax is between 3-6 hours.The average darolutamide steady-state peak plasma concentration after a 600 mg twice daily dose is approximately 4.79 mg/L. The Cmax is attained approximately 4 hours after administration of a single 600 mg oral dose. The AUC 0-12h is approximately 52.82 hg/mL. **Effects of food** The absolute bioavailability of darolutamide is approximately 30% after fasting and taking a single 300 mg dose. Steady-state concentrations are attained between 2 and 5 days after repeated administration with food. The bioavailability of darolutamide increases by 2.0 to 2.5 times when it is given with food.


Route of Elimination

In a pharmacokinetic study, a radiolabeled dose of darolutamide in an oral solution showed that 63.4% of darolutamide-related material was excreted in the urine (7% of which was unchanged drug) and 32.4% in the feces (with 30% unchanged drug).


Volume of Distribution

After intravenous administration, the apparent volume of distribution of darolutamide is about 119L.


Clearance

The clearance of darolutamide after an intravenous dose is 116 mL/min (39.7%).


5.4 Metabolism/Metabolites

Darolutamide is mainly metabolized by the CYP3A4 hepatic microsomal enzyme in addition to UGT1A9 and UGT1A1. The main active metabolite keto-darolutamide in found in the plasma at 2 times the concentration of darolutamide.


5.5 Biological Half-Life

The half-life of darolutamide and its active metabolite, keto-darolutamide is about 20 hours. A phase 1 study determined a terminal half life ranging between 10-15 hours.


5.6 Mechanism of Action

The actions of androgens on androgen receptors (AR) potentiate the growth and survival of prostate cancer cells. Darolutamide competitively inhibits androgens from binding to their receptors, inhibiting AR nuclear translocation, as well as AR-mediated transcription. The end result of these processes is a decrease in prostate cancer cell proliferation and tumor size. Its main metabolite, keto-darolutamide, shows similar pharmacological activity to the parent drug, darolutamide. Darolutamide has been found to bind more tightly to the AR receptor than [apalutamide] and [enzalutamide], which are other androgen receptor antagonists. Darolutamide can act as a progesterone receptor (PR) antagonist in the laboratory setting with approximately 1% activity when compared to its actions at the androgen receptor. The clinical relevance is not known at this time.


API SUPPLIERS

read-more
read-more

01

Biophore India Pharmaceuticals Pvt...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Biophore

02

Saiming Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSaiming Pharmaceutical – Delivering innovative, sustainable chemical solutions with global reach and 12+ years of trusted excellence.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
CB

03

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Dr Reddy Company Banner

04

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
TAPI Company Banner

05

Sichuan Qingmu Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothQingmu Pharma: Patients first, FDA/CEP/US-DMF/US-VMF/ASMF APIs for Humans & Vets in 100+ countries.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Company Banner

06

Alembic Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BPI Europe
Not Confirmed
arrow

Alembic Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BPI Europe
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

07

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BPI Europe
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BPI Europe
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

08

Changzhou Pharmaceutical Factory

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BPI Europe
Not Confirmed
arrow

Changzhou Pharmaceutical Factory

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BPI Europe
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

09

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BPI Europe
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BPI Europe
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

10

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BPI Europe
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BPI Europe
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

Bioprocess International Europe
Not Confirmed

01

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-04-20

Pay. Date : 2023-03-30

DMF Number : 37912

Submission : 2023-03-30

Status : Active

Type : II

blank

02

PCC
Not Confirmed

03

Hetero Labs Ltd

India

USDMF

arrow
Bioprocess International Europe
Not Confirmed

03

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-06-13

Pay. Date : 2023-04-25

DMF Number : 38274

Submission : 2023-05-02

Status : Active

Type : II

blank

04

Bioprocess International Europe
Not Confirmed

04

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-01-30

Pay. Date : 2023-01-09

DMF Number : 37585

Submission : 2022-11-30

Status : Active

Type : II

blank

05

Bioprocess International Europe
Not Confirmed

05

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36697

Submission : 2022-02-28

Status : Active

Type : II

blank

06

Bioprocess International Europe
Not Confirmed

06

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43200

Submission : 2025-12-15

Status : Active

Type : II

blank

07

Aurisco Pharmaceutical Co Ltd

Country

USDMF

arrow
Bioprocess International Europe
Not Confirmed

07

Aurisco Pharmaceutical Co Ltd

Country
arrow
Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43955

Submission : 2026-03-30

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Darolutamide IH

Date of Issue : 2025-09-19

Valid Till : 2028-05-05

Written Confirmation Number : WC-0349

Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

BPI Europe
Not Confirmed
arrow
arrow
BPI Europe
Not Confirmed

DAROLUTAMIDE

NDC Package Code : 68554-0140

Start Marketing Date : 2019-07-30

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

BPI Europe
Not Confirmed
arrow
arrow
BPI Europe
Not Confirmed

DAROLUTAMIDE

NDC Package Code : 54893-0107

Start Marketing Date : 2021-01-22

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

Darolutamide

About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...

Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&D center of 400 scientists, the company is a leading global API player. Biophore ranks among the top US DMF filers, holds 150+ patents and maintains a strong compliance record with major regulatory agencies. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
Biophore

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSaiming Pharmaceutical – Delivering innovative, sustainable chemical solutions with global reach and 12+ years of trusted excellence.

Flag China
Digital Content Digital Content

Darolutamide

About the Company : Saiming Pharmaceutical is a technology-driven company with 12+ years of experience. Our business involves the R&D, production, and trading of pharmaceutical intermediates, APIs, an...

Saiming Pharmaceutical is a technology-driven company with 12+ years of experience. Our business involves the R&D, production, and trading of pharmaceutical intermediates, APIs, and fine chemicals. Since its establishment, we have built major R&D and production bases across China and a global network spanning Asia, Europe, North and South America, and Africa, delivering sustainable, high-quality solutions through chemical innovation. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
CB

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Darolutamide

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
Dr Reddy Company Banner

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Darolutamide

About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...

Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios with over 350 products, alongside tailored CDMO services. Leveraging deep expertise and diverse technologies, we deliver flexible, high-quality solutions to meet our partners’ needs. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
TAPI Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothQingmu Pharma: Patients first, FDA/CEP/US-DMF/US-VMF/ASMF APIs for Humans & Vets in 100+ countries.

Flag China
Digital Content Digital Content

Darolutamide

About the Company : Sichuan Qingmu Pharmaceutical is an innovation-driven company specializing in generic APIs, advanced intermediates, and CDMO/CMO services for small-molecule drugs. Approved by US F...

Sichuan Qingmu Pharmaceutical is an innovation-driven company specializing in generic APIs, advanced intermediates, and CDMO/CMO services for small-molecule drugs. Approved by US FDA, Korea MFDS, and China NMPA, Qingmu supports global clients from early development to commercial supply, maintaining international quality standards. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

06

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Darolutamide

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

07

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Darolutamide

About the Company : Fujian Fukang Pharmaceutical Co., Ltd (Fukang) is located in Fuzhou-capital of Fujian province, founded in 1958, renamed Fuzhou Antibiotic General Factory in 1992 and became a whol...

Fujian Fukang Pharmaceutical Co., Ltd (Fukang) is located in Fuzhou-capital of Fujian province, founded in 1958, renamed Fuzhou Antibiotic General Factory in 1992 and became a wholly state-owned enterprise in 1996. In 2002 it was reformed into a corporation with a variety of shareholders. Over more than 40 years Fukang is steadily growing. Starting from a single product, its current product range includes 7ACA intermediate, sterile cephalosporin API, antibiotic API, preparation and Animal Feed. As one of the top 100 pharmaceutical enterprises in China in terms of sales volume and profit.
blank

08

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Darolutamide

About the Company : Globe Quimica S.A. is a major Brazilian API producer, GMP certificated by ANVISA, manufactures more than 20 different API's such as Antiretrovirals, Anxiolytic, Antidepressant, Ant...

Globe Quimica S.A. is a major Brazilian API producer, GMP certificated by ANVISA, manufactures more than 20 different API's such as Antiretrovirals, Anxiolytic, Antidepressant, Antithrombotic, Analgesic. In 2012 Globe Quimica has started-up its new API plant for Active Ingredients for Oncologic Drugs.
blank

09

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Darolutamide

About the Company : Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 2000. It is a state-controlled competitive listed company. Its predecessor was Yangzhou Pharmaceutical Factory, which was e...

Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 2000. It is a state-controlled competitive listed company. Its predecessor was Yangzhou Pharmaceutical Factory, which was established in 1958. It achieved A-share listing in March 2003 with the stock code "600513". After years of reform and development, the company has grown into a national high-tech enterprise integrating R&D, production and sales. It enjoys a high reputation and reputation in the domestic and foreign pharmaceutical manufacturing fields. The company’s main products include urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics etc
blank

10

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Darolutamide

About the Company : Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing p...

Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing patients across geographies and bridging the gap of unmet needs of medical fraternity through continuous innovation. Our basic business philosophy, by its very nature, serves a social responsibility hence we have a far better reason than profits alone to drive our performance. Sustainability, is not a trend we blindly follow, it is intrinsic to how we have operated since the genesis of the organization in the year 1986.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

DAROLUTAMIDE

Brand Name : NUBEQA

Dosage Form : TABLET;ORAL

Dosage Strength : 300MG

Packaging :

Approval Date : 2019-07-30

Application Number : 212099

Regulatory Info : RX

Registration Country : USA

blank

02

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

Darolutamide

Brand Name : NUBEQA

Dosage Form : Film Coated Tablet

Dosage Strength : 300mg

Packaging :

Approval Date : 19/06/2020

Application Number : 67521

Regulatory Info : Allowed

Registration Country : Switzerland

blank

03

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

Darolutamid

Brand Name : Nubeqa

Dosage Form : Film Coated Tablet

Dosage Strength : 300mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

04

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

Darolutamide

Brand Name : Nubeqa

Dosage Form : Film-Coated Tablet

Dosage Strength : 300mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

05

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

Darolutamide

Brand Name : Nubeqa

Dosage Form : Film Coated Tablet

Dosage Strength : 300MG

Packaging :

Approval Date : 04-05-2020

Application Number : 1201432001

Regulatory Info : Authorized

Registration Country : Spain

blank

06

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

Darolutamide

Brand Name : Nubeqa

Dosage Form : Film Coated Tablet

Dosage Strength : 300mg

Packaging :

Approval Date : 27-03-2020

Application Number : 28106240519

Regulatory Info : Prescription

Registration Country : Denmark

blank

07

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

Darolutamide

Brand Name : Nubeqa

Dosage Form : Film Coated Tablet

Dosage Strength : 300mg

Packaging :

Approval Date : 27-03-2020

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

08

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

DAROLUTAMIDE

Brand Name : NUBEQA

Dosage Form : TABLET

Dosage Strength : 300MG

Packaging :

Approval Date :

Application Number : 2496348

Regulatory Info : PRESCRIPTION

Registration Country : Canada

blank

09

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

Darolutamide

Brand Name : NUBEQA

Dosage Form : TAB

Dosage Strength : 300mg

Packaging : 112X1mg

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank

10

Bayer AG

Germany
Sampe
Not Confirmed
arrow

Bayer AG

Germany
arrow
Sampe
Not Confirmed

Darolutamide

Brand Name : Nubeqa

Dosage Form :

Dosage Strength :

Packaging : 112

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

Sampe
Not Confirmed
arrow
arrow
Sampe
Not Confirmed

DAROLUTAMIDE

Brand Name : NUBEQA

Dosage Form : TABLET;ORAL

Dosage Strength : 300MG

Approval Date : 2019-07-30

Application Number : 212099

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 11046713

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 212099

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-10-27

blank

02

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 9657003

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212099

Patent Use Code : U-4208

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-10-27

blank

03

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 10835515

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212099

Patent Use Code : U-4208

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-01-28

blank

04

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 9657003

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212099

Patent Use Code : U-4209

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-10-27

blank

05

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 10010530

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 212099

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-01-28

blank

06

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 8975254

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212099

Patent Use Code : U-4209

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-25

blank

07

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 10835515

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212099

Patent Use Code : U-4210

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-01-28

blank

08

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 10711013

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212099

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-10-27

blank

09

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 12329742

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212099

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2042-06-17

blank

10

arrow
PCC
Not Confirmed
arrow
PCC
Not Confirmed

DAROLUTAMIDE

US Patent Number : 10835515

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212099

Patent Use Code : U-2605

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-01-28

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 1297538-32-9 / Darolutamide API manufacturers, exporters & distributors?

Darolutamide manufacturers, exporters & distributors 1

36

PharmaCompass offers a list of Darolutamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Darolutamide manufacturer or Darolutamide supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Darolutamide manufacturer or Darolutamide supplier.

API | Excipient name

Darolutamide

Synonyms

Odm-201, 1297538-32-9, Bay-1841788, Nubeqa, Bay1841788, Darolutamide [usan]

Cas Number

1297538-32-9

Unique Ingredient Identifier (UNII)

X05U0N2RCO

About Darolutamide

Darolutamide is a formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.

Darolutamide Manufacturers

A Darolutamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Darolutamide, including repackagers and relabelers. The FDA regulates Darolutamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Darolutamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Darolutamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Darolutamide Suppliers

A Darolutamide supplier is an individual or a company that provides Darolutamide active pharmaceutical ingredient (API) or Darolutamide finished formulations upon request. The Darolutamide suppliers may include Darolutamide API manufacturers, exporters, distributors and traders.

click here to find a list of Darolutamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Darolutamide USDMF

A Darolutamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Darolutamide active pharmaceutical ingredient (API) in detail. Different forms of Darolutamide DMFs exist exist since differing nations have different regulations, such as Darolutamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Darolutamide DMF submitted to regulatory agencies in the US is known as a USDMF. Darolutamide USDMF includes data on Darolutamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Darolutamide USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Darolutamide suppliers with USDMF on PharmaCompass.

Darolutamide WC

A Darolutamide written confirmation (Darolutamide WC) is an official document issued by a regulatory agency to a Darolutamide manufacturer, verifying that the manufacturing facility of a Darolutamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Darolutamide APIs or Darolutamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Darolutamide WC (written confirmation) as part of the regulatory process.

click here to find a list of Darolutamide suppliers with Written Confirmation (WC) on PharmaCompass.

Darolutamide NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Darolutamide as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Darolutamide API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Darolutamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Darolutamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Darolutamide NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Darolutamide suppliers with NDC on PharmaCompass.

Darolutamide GMP

Darolutamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Darolutamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Darolutamide GMP manufacturer or Darolutamide GMP API supplier for your needs.

Darolutamide CoA

A Darolutamide CoA (Certificate of Analysis) is a formal document that attests to Darolutamide's compliance with Darolutamide specifications and serves as a tool for batch-level quality control.

Darolutamide CoA mostly includes findings from lab analyses of a specific batch. For each Darolutamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Darolutamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Darolutamide EP), Darolutamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Darolutamide USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty